Pay in 4 interest-free payments of $5.82 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
You may also be eligible for financial support in your province
Notably, a key feature of this approval is its link to the FDAs National Priority Voucher (CNPV) program
Development, preclinical, and early clinical data on the GIP/GLP-1 receptor agonist tirzepatide Among the GIP/GLP-1 receptor agonists, tirzepatide (LY3298176) is the compound that is the most advanced in development and the first substance in this class that has received approval for the therapy of T2D by the FDA in May 2022 (manufacturer Eli Lilly Comp., trade name Mounjaro ) (5355)
Semaglutide is a GLP-1 selective medication with strong evidence and a well-established safety profile
US$ 21.38
US$ 28.72
US$ 27.96
US$ 29.57
